CYPH Soars 52% as EPS Revisions Signal Breakout in Healthcare AI
Small-cap healthcare AI play CYPH led the pack with a 52.3% surge from $1.07 to $1.63 after analysts raised its next-year EPS growth estimate by a staggering 172.2 percentage points to 254.6%. MSTR and PRE also gained 33.1% and 32.9% respectively, driven by Bitcoin's recovery above $80K and insider purchases following strong Q2 results.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| CYPH | Healthcare | 2026-08-19 | +172.2pp | +52.3% |
| MSTR | Technology | 2026-08-18 | +5.9pp | +33.1% |
| PRE | Consumer Defensive | 2026-08-18 | +15.9pp | +32.9% |
| AZTR | Healthcare | 2026-08-21 | +8.4pp | +30.8% |
| IDAI | Technology | 2026-08-18 | +7.5pp | +24.1% |
Why did CYPH stock jump in August 2026?
CYPH surged 52.3% from $1.07 to $1.63 after analysts raised its next-year EPS growth estimate from 82.3% to 254.6%, a massive 172.2pp revision, on August 19.
The magnitude of this revision — the largest among today's detected stocks — signals consensus models dramatically underpriced Cypherpunk's earnings trajectory. No specific earnings news hit the tape, but the healthcare AI sector has been gaining momentum as investors rotate into companies with differentiated data platforms. The screener's detection captured this repricing early, and the 52% follow-through suggests institutional accumulation is still underway.
CYPH EPS revision history → · Screener snapshot from 2026-08-19 →
FAQ: CYPH
Why did CYPH stock jump in August 2026?
CYPH jumped 52.3% from $1.07 to $1.63 after analysts raised its next-year EPS growth estimate from 82.3% to 254.6% on August 19, a 172.2pp upward revision.
Is CYPH a buy after the rally?
The 254.6% EPS growth estimate implies the market is pricing in significant accretion from Cypherpunk's AI healthcare platform. However, the stock has already moved 52% in a week, and no new earnings news has confirmed the revision.
What is CYPH's EPS growth estimate?
CYPH's next-year EPS growth estimate stands at 254.6%, up from 82.3% before the August 19 revision.
Why did MSTR stock jump in August 2026?
MSTR jumped 33.1% from $92.52 to $123.19 after analysts raised its next-year EPS growth estimate from 135.4% to 141.3% on August 18, with Bitcoin's surge past $81,000 acting as the confirming catalyst.
Strategy's 840,447 BTC position flipped from a $9.5 billion paper loss to a $4.7 billion unrealized gain in under a week, vaulting its cost basis of $75,385 back into profit. Canaccord Genuity raised its target to $175 from $130, noting the setup has "materially brightened," while Bernstein's target cut to $350 still implied 175% upside. The EPS revision captured the correlation shift — as Bitcoin rallies, Strategy's accounting earnings amplify, and the 5.9pp upward revision signaled analysts were catching up to that dynamic.
MSTR EPS revision history → · Screener snapshot from 2026-08-18 →
FAQ: MSTR
Why did MSTR stock jump in August 2026?
MSTR gained 33.1% from $92.52 to $123.19 after analysts raised its EPS growth estimate to 141.3% on August 18, and Bitcoin's recovery above $81,000 pushed its $66B BTC position back into profit.
Is MSTR a buy after the rally?
Canaccord raised its target to $175 (38% upside) while Bernstein cut to $350 but maintained Outperform. The 141.3% EPS growth estimate and Bitcoin's momentum suggest continued upside, though dilution risk persists.
What caused MSTR's surge?
Bitcoin's rapid recovery from $60K to above $81,000 transformed Strategy's paper loss into a $4.7B gain, and Canaccord raised its price target to $175, supporting the stock's 33.1% climb.
Why did PRE stock jump in August 2026?
PRE jumped 32.9% from $19.40 to $25.78 after analysts raised its next-year EPS growth estimate from 51.7% to 67.6% on August 18, with CEO and CFO insider purchases of $1.0M providing confirmation.
The buys, executed between August 20-25 at ~$20.34 per share, brought leadership's cumulative personal investment to $3.75M with zero sales — a strong signal following Q2 revenue of $46.5M (up 3.9x YoY). Management raised full-year 2026 guidance to $220M-$230M, and July revenue hit $20.9M, the strongest month in company history. The EPS revision captured the inflection point; the 15.9pp increase to 67.6% reflected the General Catalyst $1B financing commitment that underwriting 70% of acquisition spend.
PRE EPS revision history → · Screener snapshot from 2026-08-18 →
FAQ: PRE
Why did PRE stock jump in August 2026?
PRE gained 32.9% from $19.40 to $25.78 after analysts raised its EPS growth estimate to 67.6% on August 18, supported by $1.0M in CEO/CFO insider purchases following record Q2 revenue.
Is PRE a buy after the rally?
The 15.9pp EPS revision to 67.6% growth, insider buying, and Q2 revenue up 3.9x YoY with a $1B financing commitment from General Catalyst support the bullish case, though the stock is now 27% above the insider purchase price.
What caused PRE's surge?
Leadership's $1.0M open-market purchases at ~$20.34, combined with raised FY2026 guidance to $220M-$230M and July's record $20.9M revenue, confirmed the EPS revision from 51.7% to 67.6%.
Why did AZTR stock jump in August 2026?
AZTR jumped 30.8% from $0.13 to $0.17 after analysts raised its next-year EPS growth estimate from 59.6% to 68.0% on August 21.
At a sub-$1 share price, the 8.4pp revision to 68% growth is meaningful — it signals analysts expect Azitra's rare-dermatology pipeline to convert into earnings sooner than previously modeled. No company-specific news emerged, but the broader healthcare biotech segment has been attracting speculative flows. The screener's early detection at $0.13 and the stock's follow-through suggest the revised estimates are drawing fresh institutional interest despite the micro-cap size.
AZTR EPS revision history → · Screener snapshot from 2026-08-21 →
FAQ: AZTR
Why did AZTR stock jump in August 2026?
AZTR gained 30.8% from $0.13 to $0.17 after analysts raised its next-year EPS growth estimate from 59.6% to 68.0% on August 21.
What caused AZTR's surge?
The 8.4pp upward EPS revision to 68% growth, indicating analysts see improved earnings potential from Azitra's dermatology pipeline, drove the 30.8% gain with no other news in the window.
Is AZTR a buy after the rally?
The 68% EPS growth estimate is encouraging, but a 30.8% move in a $0.17 stock carries elevated volatility risk. The pullback to prior levels would offer better risk-adjusted entry.
Why did IDAI stock jump in August 2026?
IDAI climbed 24.1% from $2.49 to $3.09 after analysts raised its next-year EPS growth estimate from 104.2% to 111.7% on August 18.
The 7.5pp revision to triple-digit growth stands out — T Stamp's identity-verification AI platform is apparently seeing analysts layer in stronger adoption than originally modeled. No earnings news hit the tape, but the stock's move parallels the broader AI/tech rally. The screener flagged IDAI before the move, and the 24% follow-through shows estimates are leading price discovery.
IDAI EPS revision history → · Screener snapshot from 2026-08-18 →
FAQ: IDAI
Why did IDAI stock jump in August 2026?
IDAI advanced 24.1% from $2.49 to $3.09 after analysts raised its next-year EPS growth estimate from 104.2% to 111.7% on August 18.
What is IDAI's EPS growth estimate?
IDAI's next-year EPS growth estimate is 111.7%, up from 104.2% before the August 18 revision.
Is IDAI a buy after the rally?
Triple-digit EPS growth estimates and a 24% price gain suggest momentum, but with no news confirming the revision, the move is purely estimate-driven — worth watching for follow-through volume.
Today's top performers — CYPH, MSTR, PRE, AZTR, and IDAI — show the EPS revision screener catching repricing events before price action confirms them, with an average gain of 34.6% from detection. The mix of healthcare AI, Bitcoin-correlated tech, and consumer health signals that revised estimates are cutting across sectors, pointing to a broader re-rating cycle where analysts are aggressively updating models.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →